Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (91-100 of 156) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|July 4, 2012
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902Young Hak Kim, Masataka Hirabayashi, Yosuke Togashi, et al.
Cancer Science|February 28, 2025
High Antigenicity for T<sub>reg</sub> Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in T<sub>reg</sub> CellsHiroaki Matsuura, Takamasa Ishino, Toshifumi Ninomiya, et al.
Science Immunology|February 2, 2020
Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i>-mutated non-small cell lung cancerEri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, et al.
Molecular Cancer|June 3, 2014
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerYosuke Togashi, Hiroki Sakamoto, Hidetoshi Hayashi, et al.
Cancer Letters|December 3, 2014
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancerYosuke Togashi, Akihiro Kogita, Hiroki Sakamoto, et al.
Cell Reports|February 16, 2024
Stem-like progenitor and terminally differentiated T<sub>FH</sub>-like CD4<sup>+</sup> T cell exhaustion in the tumor microenvironmentWenhao Zhou, Shusuke Kawashima, Takamasa Ishino, et al.
International Journal of Oncology|December 16, 2014
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancerAkihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, et al.
International Journal of Oncology|August 7, 2014
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transitionAkihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, et al.
Plos One|May 9, 2015
Extended RAS and BRAF Mutation Analysis Using Next-Generation SequencingKazuko Sakai, Junji Tsurutani, Takeharu Yamanaka, et al.
Pageof 16

Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|July 4, 2012
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902Young Hak Kim, Masataka Hirabayashi, Yosuke Togashi, et al.
Cancer Science|February 28, 2025
High Antigenicity for T<sub>reg</sub> Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in T<sub>reg</sub> CellsHiroaki Matsuura, Takamasa Ishino, Toshifumi Ninomiya, et al.
Science Immunology|February 2, 2020
Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i>-mutated non-small cell lung cancerEri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, et al.
Molecular Cancer|June 3, 2014
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerYosuke Togashi, Hiroki Sakamoto, Hidetoshi Hayashi, et al.
Cancer Letters|December 3, 2014
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancerYosuke Togashi, Akihiro Kogita, Hiroki Sakamoto, et al.
Cell Reports|February 16, 2024
Stem-like progenitor and terminally differentiated T<sub>FH</sub>-like CD4<sup>+</sup> T cell exhaustion in the tumor microenvironmentWenhao Zhou, Shusuke Kawashima, Takamasa Ishino, et al.
International Journal of Oncology|December 16, 2014
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancerAkihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, et al.
International Journal of Oncology|August 7, 2014
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transitionAkihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, et al.
Plos One|May 9, 2015
Extended RAS and BRAF Mutation Analysis Using Next-Generation SequencingKazuko Sakai, Junji Tsurutani, Takeharu Yamanaka, et al.
Pageof 16